IL-UNITAS-GLOBAL
22.2.2021 14:03:13 CET | Business Wire | Press release
Unitas Global announces the availability of Unitas Reach™ , the first global software defined network (SDN) to offer automated ubiquitous edge access to any cloud location. Enterprises are finding that current networks are a bottleneck to the adoption of new technologies and capabilities – these problems have not been resolved, until now. Unitas Reach™ is the industry's first purpose-built network connecting cloud providers, carrier-neutral data centers, SaaS applications, and edge access networks to form a multi-service global interconnection fabric.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210222005156/en/
"Organizations today need flexible, proven, and secure infrastructure to run their enterprise applications and multi-cloud solutions," shares Patrick Shutt, CEO of Unitas Global. "With Unitas Reach™, our clients achieve cost-optimized network connectivity with the agility needed to scale quickly and support the growing demands of applications on network architectures, performance, and costs."
Unitas Reach™ is built to provide connectivity options that different modern cloud services require with simple integration to traditional enterprise networks. With its presence on six continents, Unitas Reach™ provides redundant and diverse Internet, IP, Ethernet, and Wave access to distributed applications across any cloud, hybrid-cloud, multi-cloud, or private cloud destination. Strategic interconnections with hundreds of other networks and fiber access providers further extends the network access to the edge, including over 900 carrier neutral data centers and 30 million enterprise locations in over 85 countries. Sophisticated automation, monitoring, and orchestration to the edge make the entire interconnect fabric unmatched in enabling complete flexibility in service creation and scaling capacity as enterprise networking needs change.
"We designed Unitas Reach™ in response to the dynamic networking requirements that today's businesses require and have yet to experience," comments Grant Kirkwood, Founder and CTO of Unitas Global. "Providers and enterprises can easily add connectivity to dynamically support their ever changing network strategies, and customize capabilities to their unique set of service delivery, operations, access and configuration requirements.”
Unitas' edge to everywhere connectivity solutions offer providers and enterprises with automated:
- Cloud On-ramps™ for multi-cloud delivery
- High performance managed Internet
- Direct connectivity to and between multi-cloud platforms
- Agile and scalable WAN solutions
Unitas Reach™ provides the greatest choice and ease of use for provisioning enterprises with connectivity that delivers agile, cost-effective, low-latency connections to optimize application performance. Unitas Global solves the enterprise challenge by going to market with MSPs, hyperscalers, and data centers who are able to establish an on-net point of presence with Unitas Reach™ to expand their network coverage, scale services everywhere, and locate applications as close to customers as possible to improve performance and optimize costs.
Learn more about Unitas Reach™ and its edge to everywhere connectivity solution.
About Unitas Global
Unitas Global is a global managed network service provider offering automated ubiquitous edge access to any cloud, everywhere. The company provides the most agile connected multi-cloud environments that are easy-to-consume, fully managed, and backed by a promise to deliver the best application performance. Connect with Unitas at LinkedIn , Twitter , and its Blog .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005156/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release
Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom